AR019579A1 - USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS - Google Patents

USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS

Info

Publication number
AR019579A1
AR019579A1 ARP990102489A ARP990102489A AR019579A1 AR 019579 A1 AR019579 A1 AR 019579A1 AR P990102489 A ARP990102489 A AR P990102489A AR P990102489 A ARP990102489 A AR P990102489A AR 019579 A1 AR019579 A1 AR 019579A1
Authority
AR
Argentina
Prior art keywords
sexual response
nervous system
initiator
central nervous
produce
Prior art date
Application number
ARP990102489A
Other languages
English (en)
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston filed Critical Univ Kingston
Publication of AR019579A1 publication Critical patent/AR019579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona, en una realizacion, un método de normalizacion de la cronometracion de la respuesta sexual en un mamífero, consistenteen la administracion de una cantidad de un iniciador de la respuesta sexual del sistema nerviosocentral en una cantidad suficiente para producirvasodilatacion genital, pero menor que la cantidad necesaria para producir estimulacion vasocongestiva efectiva. El método es aplicable no solo al ajuste o lanormalizacion de la cronometracion de la respuesta sexual en humanos, sino en la reproduccion de animales que tienen un valor comercial, tales como caballos,ganado vacuno, ovejas, cerdos y similares y mascotas domesticadas, tales como perros y gatos. En una realizacion alternativa, la presenteinvencion proporcionaun método para el tratamiento profiláctico de la degradacion de tejidos a largo plazo en los organos genitales, consistente en la administracion a unmamífero de un iniciador de la respuesta sexual del sistema nervioso central enuna cantidad necesaria para producir estimulacion vasocongestiva efectiva. Eliniciador preferido de la respuesta sexual del sistema nervioso central es la apomorfina o una sal de adicion de ácido farmacéuticamente aceptable de la misma.
ARP990102489A 1998-05-29 1999-05-27 USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS AR019579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/086,630 US6403605B1 (en) 1998-05-29 1998-05-29 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation

Publications (1)

Publication Number Publication Date
AR019579A1 true AR019579A1 (es) 2002-02-27

Family

ID=22199842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102489A AR019579A1 (es) 1998-05-29 1999-05-27 USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS

Country Status (11)

Country Link
US (3) US6403605B1 (es)
EP (2) EP1666040A1 (es)
AR (1) AR019579A1 (es)
AT (1) ATE326969T1 (es)
AU (1) AU764009B2 (es)
CA (1) CA2331387A1 (es)
DE (1) DE69931487T2 (es)
ES (1) ES2268869T3 (es)
HK (1) HK1037517A1 (es)
TW (1) TWI232748B (es)
WO (1) WO1999062502A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
WO2008100933A2 (en) * 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Reducing side effects of tramadol
US20110150946A1 (en) * 2008-08-22 2011-06-23 Al-Ghananeem Abeer M Transdermal Delivery of Apomorphine Using Microneedles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
ATE290864T1 (de) 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
DE69514794T2 (de) 1994-04-22 2000-07-27 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
TR199800628T2 (xx) 1995-10-13 1998-07-21 Neurosearch A/S 8-Azabisiklo$3.2.1]okt-2-en t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.

Also Published As

Publication number Publication date
DE69931487D1 (de) 2006-06-29
ES2268869T3 (es) 2007-03-16
US20030092725A1 (en) 2003-05-15
TWI232748B (en) 2005-05-21
WO1999062502A3 (en) 2000-06-15
ATE326969T1 (de) 2006-06-15
EP1082118A2 (en) 2001-03-14
EP1666040A1 (en) 2006-06-07
DE69931487T2 (de) 2007-05-03
AU764009B2 (en) 2003-08-07
HK1037517A1 (en) 2002-02-15
CA2331387A1 (en) 1999-12-09
US6403605B1 (en) 2002-06-11
EP1082118B1 (en) 2006-05-24
WO1999062502A2 (en) 1999-12-09
US20060281752A1 (en) 2006-12-14
AU4027299A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
AR045142A1 (es) Composicion veterinaria masticable ductil de buen sabor
Prunier et al. Identifying and monitoring pain in farm animals: a review
Friend Behavioral aspects of stress
AR019579A1 (es) USO DE UN INICIADOR DE LA RESPUESTA SEXUAL DEL SISTEMA NERVIOSO CENTRAL PARA LA FABRICACIoN DE UNA COMPOSICIoN FARMACÉUTICA PARA LA NORMALIZACIoN DE LA CRONOMETRACIoN DE LA RESPUESTA SEXUAL O PARA LA PROFILAXIS O REDUCCIoN DE LA LESIoN TISULAR GENITAL EN MAMíFEROS
BR0013116A (pt) Tratamento oral de animais de estimação com espinosinas ectoparasiticidas
BRPI0517719A (pt) composição veterinária transmucosal compreendendo detomidina
AR098251A2 (es) Uso de aivlosin o de una sal de adición ácida del mismo farmacológicamente aceptada para la preparación de un medicamento de uso veterinario, un alimento para aves de corral o cerdos, una composición recubierta estable para ser agregada a dicho alimento y un medicamento de uso veterinario
Winter Lameness in sheep 2. Treatment and control
WO2011011843A1 (pt) Método químico para esterilização sexual e eliminação da libido em mamíferos do sexo masculino
ES2928468T3 (es) Gestión del estrés en ganado
RU2473338C1 (ru) Способ лечения и профилактики бабезиоза северных оленей
Jesse et al. Clinical management of severe cutaneous myiasis in a brangus-cross calf
Seid et al. Non-surgical castration methods to control stray dog population, a review
Fordyce et al. Postoperative healing and behaviour when surgical swabs are applied to calf dehorning wounds
Lawrence et al. Diseases of backyard pigs in New Zealand
BR9811004A (pt) "tratamento e prevenção de distúrbios cardìacos usando inibidores seletivos (ssri) da reelevação do nìvel de serotonina"
Majid et al. Care and management of wound in animals
ES2949316T3 (es) Uso oral de gluconatos de zinc y cobre en el tratamiento de la dermatitis digital
Borthakur et al. CUTANEOUS HABRONEMIASIS IN EQUINE.
Pozzi et al. Legislation and Practices in Israel for the Protection of Pigs from Unnecessary Pain: Mutilations in Piglets
KR20220041862A (ko) 크립토스포리듐증의 예방 및/또는 치료를 위한 수의학적 조성물
Abbas et al. Parenteral Combined with Topical Treatment of Navel Ill in Cow Calves.
Safdar Abbas et al. Parenteral combined with topical treatment of navel ill in cow calves.
Dangolla Some Traditional Captive Elephant Management Practices in Sri Lanka
BR112021015389A2 (pt) Composição para tratamento e/ou prevenção de doenças infecciosas do casco

Legal Events

Date Code Title Description
FB Suspension of granting procedure